NeuroSense Therapeutics Ltd. has announced a strategic collaboration agreement aimed at advancing its lead therapeutic candidate, PrimeC, for patients with Amyotrophic Lateral Sclerosis (ALS). This agreement is significant as it positions the company to potentially generate revenue by supplying PrimeC through a licensed clinical treatment center in the United States.
The commercialization of PrimeC is expected to occur through a pathway that may allow access to investigational therapies before traditional marketing approval. NeuroSense is targeting its first revenues from the PrimeC supply in the first half of 2027, contingent upon completing necessary legal, regulatory, and operational requirements.
This agreement comes in response to sustained demand from ALS patients and physicians seeking access to PrimeC outside of clinical trials. As part of the collaboration, NeuroSense will compensate the advisor in equity and a success-based percentage of net revenues generated from qualifying sales resulting from the advisor's efforts.
NeuroSense's agreement is intended to support its efforts in establishing an initial revenue stream from PrimeC supply, marking a pivotal transition toward a revenue-generating business model while it continues its clinical programs in ALS and Alzheimer’s disease.
NeuroSense Therapeutics Ltd. operates under the SIC classification of Pharmaceutical Preparations. The company is listed on the Nasdaq under the tickers NRSN and NRSNW and is categorized as a non-accelerated filer and an emerging growth company.
The filing does not specify what happens next regarding the collaboration or further developments related to PrimeC.